As previously shown, such cells also have a narrow phenotype in gut and blood of untreated CeD patients.[6] Together, these findings indicate that gluten‐specific CD4+ T cells can be therapeutically targeted within different disease states. Here, CD4 is linked to cranioectodermal dysplasia.